Introducing the characteristics of Endolysin as an alternative to antibiotics

authors:

avatar Farnoosh Majlesain , avatar Shamsozoha Abolmaali , avatar Shakiba Darvish Alipour Astaneh , * , avatar Nooshin Bijari

Koomesh: Vol.25, issue 4; 407-419
published online: September 02, 2023
article type: Research Article
received: February 01, 2023
accepted: August 02, 2023

how to cite: Majlesain F, Abolmaali S, Darvish Alipour Astaneh S, Bijari N. Introducing the characteristics of Endolysin as an alternative to antibiotics. koomesh. 2023;25(4):e152839. 

Abstract

The emergence of antibiotic-resistant bacterial strains has become a global crisis for public health. There are many concerns about the increase of multi-drug resistant bacteria so that some diseases cannot be effectively treated. There is an urgent need to develop alternatives to conventional antibiotics for human and animal treatment. As an alternative to antibiotics, endolysins are interesting due to their high antibacterial activity and properties against numerous bacterial pathogens and in various fields of application, including medicine, food safety, and agriculture. Most phage endolysins show a wide spectrum of activity. Several features of these enzymes, including their high activity, are the presence of two catalytic domains in their structure, which further reduces the possibility of resistance formation, also, the mechanism of action and their type of lytic activity support their further exploitation as valuable and strong antibacterial agents for the treatment of infections. In this review, the structure and mechanism of endolysin, as well as its benefits as an alternative to antibiotics, and the problems in this field are stated. Moreover, the applications and advances of endolysin have been reviewed, and the newly engineered endolysins as potential candidates have been introduced.

References

  • 1.

    Mirhoseini SH, Nikaeen M, Shamsizadeh Z, Aali R. Prevalence and molecular identification of antibiotic resistant airborne bacteria at intensive care units. Koomesh 2018; 20: 772-778. (Persian).

  • 2.

    Frieri M, Kumar K, Boutin A. Antibiotic resistance. J Infect Public Health 2017; 10: 369-378.

  • 3.

    Falco A, Medina-Gali RM, Poveda JA, Bello-Perez M, Novoa B, Encinar JA. Antiviral activity of a Turbot (Scophthalmus maximus) NK-lysin peptide by inhibition of low-pH virus-induced membrane fusion. Mar Drugs 2019; 17: 87.

  • 4.

    Tahmasebi H, Dehbashi S, Arabestani MR. Resistance pattern to macrolides and tetracyclines and detection of ermA, ermB, emrC and mphc genes in clinical isolates of Staphylococcus aureus producing toxic shock syndrome toxin-1. Koomesh 2018; 21: 188-194. (Persian).

  • 5.

    Caflisch KM, Patel R. Implications of bacteriophage-and bacteriophage component-based therapies for the clinical microbiology laboratory. J Clin Microbiol 2019; 57: e00229-19.

  • 6.

    Walmagh M. Development and evaluation of engineered bacteriophage endolysins to inactivate Gram-negative bacteria. 2013.

  • 7.

    Wittebole X, De Roock S, Opal SM. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 2014; 5: 226-235.

  • 8.

    Gordillo Altamirano FL, Barr JJ. Phage therapy in the postantibiotic era. Clin Microbiol Rev 2019; 32: e00066-18.

  • 9.

    C. Loc-Carrillo and S. T. Abedon. Pros and cons of phage therapy. Bacteriophage 2011; 1: 111-114.

  • 10.

    Doss J, Culbertson K, Hahn D, Camacho J, Barekzi N. A review of phage therapy against bacterial pathogens of aquatic and terrestrial organisms. Viruses 2017; 9: 50.

  • 11.

    F. Abdelrahman et al. Phage-encoded endolysins. Antibiotics 2021; 10: 124.

  • 12.

    Murray E, Draper LA, Ross RP, Hill C. The advantages and challenges of using endolysins in a clinical setting. Viruses 2021; 13: 680.

  • 13.

    Chu JJ, Poh WH, Hasnuddin NT, Hew EY, Dam LC, Sahili AE, et al. Novel phage lysin Abp013 against Acinetobacter baumannii. Antibiotics 2022; 11: 169.

  • 14.

    Gontijo MT, Jorge GP, Brocchi M. Current status of endolysin-based treatments against Gram-negative bacteria. Antibiotics 2021; 10: 1143.

  • 15.

    Bragg RR, Meyburgh CM, Lee JY, Coetzee M. Potential treatment options in a post-antibiotic era. Infect Dis Nanomedicine III 2018; 51-61.

  • 16.

    Love MJ, Abeysekera GS, Muscroft-Taylor AC, Billington C, Dobson RC. On the catalytic mechanism of bacteriophage endolysins: Opportunities for engineering. Biochim Biophys Acta 2020; 1868: 140302.

  • 17.

    Gondil VS, Harjai K, Chhibber S. Endolysins as emerging alternative therapeutic agents to counter drug-resistant infections. Int J Antimicrob Agents 2020; 55: 105844.

  • 18.

    Fischetti VA. Bacteriophage lysins as effective antibacterials. Curr Opin Microbiol 2008; 11: 393-400.

  • 19.

    Van Tassell ML, Ibarra-Snchez LA, Hoepker GP, Miller MJ. Hot topic: Antilisterial activity by endolysin PlyP100 in fresh cheese. J Dairy Sci 2017; 100: 2482-2487.

  • 20.

    Cho JH, Kwon JG, O'Sullivan DJ, Ryu S, Lee JH. Development of an endolysin enzyme and its cell wall-binding domain protein and their applications for biocontrol and rapid detection of Clostridium perfringens in food. Food Chem 2021; 345: 128562.

  • 21.

    Shannon R, Radford DR, Balamurugan S. Impacts of food matrix on bacteriophage and endolysin antimicrobial efficacy and performance. Crit Rev Food Sci Nutr 2020; 60: 1631-1640.

  • 22.

    Ribelles P, Benbouziane B, Langella P, Surez JE, Bermdez-Humarn LG, Riazi A. Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface. Appl Microbiol Biotechnol 2013; 97: 1231-1239.

  • 23.

    Hu S, Kong J, Kong W, Guo T, Ji M. Characterization of a novel LysM domain from Lactobacillus fermentum bacteriophage endolysin and its use as an anchor to display heterologous proteins on the surfaces of lactic acid bacteria. Appl Environ Microbiol 2010; 76: 2410-2418.

  • 24.

    Kim WS, Salm H, Geider K. Expression of bacteriophage Ea1h lysozyme in Escherichia coli and its activity in growth inhibition of Erwinia amylovora. Microbiology 2004; 150: 2707-2714.

  • 25.

    Schmelcher M, Loessner MJ. Bacteriophage endolysins: applications for food safety. Curr Opin Biotechnol 2016; 37: 76-87.

  • 26.

    Rodrguez-Rubio L, Gutirrez D, Donovan DM, Martnez B, Rodrguez A, Garca P. Phage lytic proteins: biotechnological applications beyond clinical antimicrobials. Crit Rev Biotechnol 2016; 36: 542-552.

  • 27.

    Doehn JM, Fischer K, Reppe K, Gutbier B, Tschernig T, Hocke AC, et al. Delivery of the endolysin Cpl-1 by inhalation rescues mice with fatal pneumococcal pneumonia. J Antimicrob Chemother 2013; 68: 2111-2117.

  • 28.

    Haddad Kashani H, Schmelcher M, Sabzalipoor H, Seyed Hosseini E, Moniri R. Recombinant endolysins as potential therapeutics against antibiotic-resistant Staphylococcus aureus: current status of research and novel delivery strategies. Clin Microbiol Rev 2018; 31: e00071-17.

  • 29.

    Schmelcher M, Waldherr F, Loessner MJ. Listeria bacteriophage peptidoglycan hydrolases feature high thermoresistance and reveal increased activity after divalent metal cation substitution. Appl Microbiol Biotechnol 2012; 93: 633-643.

  • 30.

    Haddad Kashani H, Fahimi H, Dasteh Goli Y, Moniri R. A novel chimeric endolysin with antibacterial activity against methicillin-resistant Staphylococcus aureus. Front Cell Infect Microbiol 2017; 7: 290.

  • 31.

    Son B, Kong M, Lee Y, Ryu S. Development of a novel chimeric endolysin, Lys109 with enhanced lytic activity against Staphylococcus aureus. Front Microbiol 2021; 11: 615887.

  • 32.

    Mao J, Schmelcher M, Harty WJ, Foster-Frey J, Donovan DM. Chimeric Ply187 endolysin kills Staphylococcus aureus more effectively than the parental enzyme. FEMS Microbiol Lett 2013; 342: 30-36.

  • 33.

    Becker SC, Roach DR, Chauhan VS, Shen Y, Foster-Frey J, Powell AM, et al. Triple-acting lytic enzyme treatment of drug-resistant and intracellular Staphylococcus aureus. Sci Rep 2016; 6: 1-10.

  • 34.

    Parmley S. Lysin in wait. Sci Exch 2014; 7: 1369.

  • 35.

    Rahman MU, Wang W, Sun Q, Shah JA, Li C, Sun Y, et al. Endolysin, a promising solution against antimicrobial resistance. Antibiotics 2021; 10: 1277.

  • 36.

    Briers Y, Lavigne R. Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria. Future Microbiol 2015; 10: 377-390.

  • 37.

    Gerstmans H, Rodrguez-Rubio L, Lavigne R, Briers Y. From endolysins to Artilysin s: novel enzyme-based approaches to kill drug-resistant bacteria. Biochem Soc Trans 2016; 44: 123-128.

  • 38.

    Reyes A, Semenkovich NP, Whiteson K, Rohwer F, Gordon JI. Going viral: next-generation sequencing applied to phage populations in the human gut. Nat Rev Microbiol 2012; 10: 607-617.

  • 39.

    Kortright KE, Chan BK, Koff JL, Turner PE. Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe 2019; 25: 219-232.

  • 40.

    Schmelcher M, Loessner MJ. Bacteriophage endolysins-Extending their application to tissues and the bloodstream. Curr Opin Biotechnol 2021; 68: 51-59.

  • 41.

    Fischetti VA. Exploiting what phage have evolved to control gram-positive pathogens. Bacteriophage 2011; 1: 188-194.

  • 42.

    Roach DR, Donovan DM. Antimicrobial bacteriophage-derived proteins and therapeutic applications. Bacteriophage 2015; 5: e1062590.

  • 43.

    Porfrio S, Carlson RW, Azadi P. Elucidating peptidoglycan structure: an analytical toolset. Trends Microbiol 2019; 27: 607-622.

  • 44.

    Nelson D, Schuch R, Chahales P, Zhu S, Fischetti VA. PlyC: a multimeric bacteriophage lysine. Proc Natl Acad Sci 2006; 103: 10765-10770.

  • 45.

    Nelson D, Loomis L, Fischetti VA. Prevention and elimination of upper respiratory colonization of mice by group A Streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci 2001; 98: 4107-4112.

  • 46.

    Loeffler JM, Nelson D, Fischetti VA. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 2001; 294: 2170-2172.

  • 47.

    Varea J, Monterroso B, Siz JL, Lpez-Zumel C, Garcia JL, Laynez J, et al. Structural and thermodynamic characterization of Pal, a phage natural chimeric lysin active against pneumococci. J Biol Chem 2004; 279: 43697-43707.

  • 48.

    Rodrguez-Rubio L, Martnez B, Rodrguez A, Donovan DM, Garca P. Enhanced staphylolytic activity of the Staphylococcus aureus bacteriophage vB_SauS-phiIPLA88 HydH5 virion-associated peptidoglycan hydrolase: fusions, deletions, and synergy with LysH5. Appl Environ Microbiol 2012; 78: 2241-2248.

  • 49.

    Loessner MJ, Wendlinger G, Scherer S. Heterogeneous endolysins in Listeria monocytogenes bacteriophages: a new class of enzymes and evidence for conserved holin genes within the siphoviral lysis cassettes. Mol Microbiol 1995; 16: 1231-1241.

  • 50.

    Loessner MJ, Kramer K, Ebel F, Scherer S. Cterminal domains of Listeria monocytogenes bacteriophage murein hydrolases determine specific recognition and highaffinity binding to bacterial cell wall carbohydrates. Mol Microbiol 2002; 44: 335-349.

  • 51.

    Briers Y, Peeters LM, Volckaert G, Lavigne R. The lysis cassette of bacteriophage KMV encodes a signal-arrest-release endolysin and a pinholin. Bacteriophage 2011; 1: 25-30.

  • 52.

    Walmagh M, Boczkowska B, Grymonprez B, Briers Y, Drulis-Kawa Z, Lavigne R. Characterization of five novel endolysins from Gram-negative infecting bacteriophages. Appl Microbiol Biotechnol 2013; 97: 4369-4375.

  • 53.

    Mikoulinskaia GV, Odinokova IV, Zimin AA, Lysanskaya VY, Feofanov SA, Stepnaya OA. Identification and characterization of the metal iondependent lalanoyldglutamate peptidase encoded by bacteriophage T5. FEBS J 2009; 276: 7329-7342.

  • 54.

    Kim B, Kim ES, Yoo YJ, Bae HW, Chung IY, Cho YH. Phage-derived antibacterials: Harnessing the simplicity, plasticity, and diversity of phages. Viruses 2019; 11: 268.